

**REMARKS**

By the present amendment, new claims 111-114 are presented which provide for controlled release Galenical formulation of Claim 14 or 44 to be in capsule or tablet form. These claims find explicit support in the as-filed disclosure, and the original claims, *e.g.*, claims 7 and 8.

**Applicants note that this application has been refiled so that Applicants may submit a declaration by an expert in the art and conduct an interview with Examiner Tran to discuss the outstanding issues in this application.** This interview is set to take place on February 22, 2005 at 1:00 P.M. as agreed to by Supervisory Examiner Page on behalf of Examiner Tran.

The outstanding rejections stand traversed for the reasons of record, *e.g.*, as set forth in the Applicants' Reply to the non-final rejection dated November 18, 2002.


If there are any questions regarding this amendment or the application in general, a telephone call to the undersigned would be appreciated since this should expedite the prosecution of the application for all concerned.

If necessary to effect a timely response, this paper should be considered as a petition for an Extension of Time sufficient to effect a timely response, and

please charge any deficiency in fees or credit any overpayments to Deposit  
Account No. 05-1323 (Docket #100338.55780US).

Respectfully submitted,

January 26, 2005



---

Robin L. Teskin  
Registration No. 35,030

CROWELL & MORING LLP  
Intellectual Property Group  
P.O. Box 14300  
Washington, DC 20044-4300  
Telephone No.: (202) 624-2500  
Facsimile No.: (202) 628-8844  
RLT:elew

357576